A Phase 1 interventional study of Saxagliptin and Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.
Sponsored by AstraZeneca · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 51st largest by enrollment, is one of 12 that started in 2012, is one of 14 in phase 1, and was the 43rd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 4 · Phase 3 28 · Phase 4 25
First in 2003; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 138 across the 74 interventional studies. Of the 64 that completed or were terminated, 47 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 74 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 204th largest by enrollment of the 280 interventional ones that give a count, is one of 15 that started in 2012, is one of 86 in phase 1, and was the 216th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing saxagliptin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
Drug: Saxagliptin · Drug: Dapagliflozin
Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
Drug: Saxagliptin · Drug: Dapagliflozin
Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
Drug: Saxagliptin · Drug: Dapagliflozin
Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
Drug: Saxagliptin · Drug: Dapagliflozin
Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
Drug: Saxagliptin · Drug: Dapagliflozin
Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
Drug: Saxagliptin · Drug: Dapagliflozin
Also known as: Onglyza®, BMS-477118
Also known as: BMS-512148
Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population
The geometric mean of the maximum observed plasma concentration (Cmax) is presented below; serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h,and 60 h postdose, relative to dosing on Day 1 in each cross over period and these data are summarized in the Pharmacokinetic (PK) parameter of Cmax presented here. Plasma samples were analyzed for dapagliflozin by High Performance Liquid chromatography-Mass Spectrometry (HPLC-MS/MS) using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Dapagliflozin Cmax was derived from plasma concentration versus time data using a non-compartmental method, using a validated PK analysis program ™. Actual sampling times were used for PK calculations. Cmax was reported in ng/mL.
Time frame: Day 1 (0 h to 60 h post dose) in each period
Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population
AUC(INF) is area under the plasma concentration-time curve from time 0 extrapolated to infinity. Serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Actual sampling times were used for PK calculations. AUC(INF) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
Time frame: Day 1 (0h to 60h post dose) in each period
Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin
AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method). Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Actual sampling times were used for PK calculations. AUC(0-T) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
Time frame: Day 1 (0h to 60h post dose) in each period
Maximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). Cmax for Saxagliptin was derived from plasma concentration versus time data using a validated PK analysis program ™ and was measured in nanograms per milliliter (ng/mL).
Time frame: Day 1 (0h to 60h post dose) in each period
AUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(0-T), the area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
Time frame: Day 1 (0h to 60h post dose) in each period
AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
Time frame: Day 1 (0h to 60h post dose) in each period
Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. Tmax was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours.
Time frame: Day 1 (0h to 60h post dose) in each period
Half-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours.
Time frame: Day 1 (0h to 60h post dose) in each period
Plasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. CLT/F was calculated as Dose/AUC(INF)and was measured in milliliters per minute (mL/min).
Time frame: Day 1 (0h to 60h post dose) in each period
Cmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). Actual sampling times were used for PK calculations. Cmax for 5-OH Saxagliptin (the major active metabolite of Saxagliptin) was derived from plasma concentration versus time data using a validated PK analysis program ™ and was measured in ng/mL.
Time frame: Day 1 (0h to 60h post dose) in each period
AUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method)and was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™. AUC (0-T) was measured in nanograms\*hours per milliliter (ng\*h/mL).
Time frame: Day 1 (0h to 60h post dose) in each period
AUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
Time frame: Day 1 (0h to 60h post dose) in each period
Cmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Cmax of saxagliptin total active moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin) was derived from the plasma concentration versus time profile for the saxagliptin total active moiety. Measurement was in nano Molars (nM).
Time frame: Day 1 (0h to 60h post dose) in each period
AUC(INF) and AUC(0-T) of the Saxagliptin Total Active Moiety From a Single Dose 5 mg Saxagliptin Versus AUC(INF) and AUC(0-T) of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. AUC(INF) is area under the plasma concentration-time curve from time zero extrapolated to infinity; AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) and both were derived from the plasma concentration versus time profile using a validated PK analysis program ™. Total moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin), AUC(0-T)and AUC(INF) were measured in nano Molars\*hours (nM\*h).
Time frame: Day 1 (0h to 60h post dose) in each period
Tmax of Saxagliptin, 5-OH Saxagliptin, Saxagliptin Total Active Moiety From a Single Dose of Saxagliptin Versus Tmax of Saxagliptin, 5-OH, Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin and 5-OH by LC-MS/MS using a validated method. Tmax was derived from the plasma concentration versus time profile for study drug and was measured in hours (h). Saxagliptin was the drug, 5-OH saxagliptin was the metabolite, and Saxagliptin total Active Moiety was molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin.
Time frame: Day 1 (0h to 60h post dose) in each period
Half-life (T-HALF) of Saxagliptin, and 5-OH Saxagliptin From Single Dose 5 mg Saxagliptin Versus T-HALF of Saxagliptin and 5-OH From Co-administered Saxagliptin With 10 mg Dapagliflozin - PK Evaluable Population
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours (h).
Time frame: Day 1 (0h to 60h post dose) in each period
Metabolite to Parent Molar Ratios (MR) of Cmax, AUC(INF), and AUC(0-T) of 5-OH Saxagliptin and Saxagliptin From a Single Dose 5 mg Saxagliptin Versus MR of Saxagliptin and 5-OH When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Saxagliptin is the parent drug and 5-OH saxagliptin is the metabolite. The molecular weights to be used for the molar ratios were 315.42 and 331.42 for saxagliptin and 5-OH, respectively. Plasma samples were analyzed for saxagliptin and for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL and 0.200 ng/mL to 100.0 ng/mL for saxagliptin and 5-OH, respectively).
Time frame: Day 1 (0h to 60h post dose) in each period
Number of Participants With Deaths, Serious Adverse Events, Adverse Events, or Discontinuations Due to Adverse Events - Safety Population
Adverse event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE)=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. End of study was approximately 16 days and was the time for a participant to conclude each of the 3 periods (including the 6 day washout between periods).
Time frame: Day 1 to end of study (16 days)
Number of Participants With Marked Hematology Laboratory Abnormalities - Safety Population
Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal (LLN); upper limit of normal (ULN); pretreatment(pre-RX); treatment (RX). Hemoglobin (g/L): \<0.85\* pre-RX; hematocrit (vol): \<0.85\*pre-RX; erythrocytes (\*10\^12 c/L): \<0.85\*pre-RX; platelet count (\*10\^9 c/L): \<0.85\*LLN if pre-RX\>=LLN, or if Pre-Tx \<LLN; leukocytes (\*10\^9 c/L): \<0.85\*LLN if pre-RX \<LLN,or \<0.9\*LLN if LLN\<=Pre-RX\<=ULN; neutrophils+bands (\*10\^9 c/L): \<0.85\*Pre-RX if Pre-RX \<1.5 or \<1.5 if Pre-RX \>=1.5; eosinophils (\*10\^9 c/L): if value \>0.75; basophils (\*10\^9 c/L): if value \>0.4; monocytes (\*10\^9c/L): if value \>2; lymphocytes (\*10\^9 c/L): if value \<0.750 or if value \>7.50.
Time frame: Baseline to Day 1 of each period
Mean Change From Baseline in Systolic and Diastolic Blood Pressure - Safety Population
Blood pressure was taken while the participant was quietly seated for at least 5 minutes. Blood pressure was measured in millimeters of mercury (mmHg). Baseline was Day -1 in Period 1; study drug was administered on Day 1 of each crossover period.
Time frame: Baseline to Day 1 of each period
Mean Change From Baseline in Heart Rate - Safety Population
Heart rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in beats per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.
Time frame: Baseline to Day 1 in each period
Mean Change From Baseline in Respiration Rate - Safety Population
Respiration rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in breaths per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.
Time frame: Baseline to Day 1 in each period
Mean Change From Baseline in Temperature - Safety Population
Participant had their temperature taken after quietly sitting for at least 5 minutes and it was measured as degrees of centigrade (C). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.
Time frame: Baseline to Day 1 in each period
Number of Participants With Marked Chemistry Laboratory Abnormalities - Safety Population
Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal(LLN); upper limit of normal (ULN); pre-treatment(Pre-Rx). Alkaline phosphatase U/L:\>1.25\*Pre-RX if Pre-Rx \>ULN or \>1.25\*ULN if Pre-Rx \<=ULN; aspartate aminotransferase (AST) U/L: \>1.25\*Pre-Rx if Pre-Rx \> ULN or 1.25\*ULN if Pre-Rx \<= ULN;alanine aminotransferase (ALT) U/L: \>1.25\*Pre-Rx if Pre-Rx\>ULN or 1.25\*ULN if Pre-Rx\<=ULN;blood urea nitrogen (BUN)mmol/L: \>1.1\*ULN if Pre-Rx \<=ULN or \>1.2\*Pre-Rx if Pre-Rx \>ULN; total bilirubin µmol/L: \>1.1\*ULN if Pre-Rx \<=ULN or \>1.25\*Pre-Rx if Pre-Rx \>ULN;direct bilirubin µmol/L: \>1.1\*ULN if Pre-Rx \<= ULN or \>1.25\*Pre-Rx if Pre-Rx \> ULN; creatine phosphokinase (CK) U/L: \>1.5\*Pre-Rx if Pre-Rx \>ULN or \>1.5\*ULN if Pre-Rx \<= ULN.
Time frame: Baseline to Day 1 in each period
Number of Participants With Marked Urinalysis Laboratory Abnormalities - Safety Population
Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Fasted for 10 hours prior to samples taken. LLN=lower limit of normal; ULN=upper limit of normal; pretreatment (Pre-Rx). Normals: Urine glucose qualitative: dipstick \>=1 if Pre-Rx \<1 or 2\*Pre-Rx if Pre-Rx\>=1; urine microscopic white blood cell count (WBC): \>=2 if Pre-Rx \<2 or \>=4 if Pre-Rx \>=2;urine red blood cell count (RBC):\>=2 if Pre-Rx \<2 or \>=4 if Pre-Rx \>=2.
Time frame: Baseline to Day 1 of each period
Number of Participants With Change From Baseline in ECG Interval - Safety Population
A 12-Lead electrocardiogram (ECG) was performed and recorded after the participant had been supine for at least 5 minutes. ECGs done at baseline (Day-1 of Period 1) and at end of study; therefore the results are presented by sequence, and cannot be presented by treatment. QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec). Abnormality criteria: QT/QTcF QT or QTcF \>450 msec and \<=480 msec at any postdose time point and not present at baseline. QT or QTcF \>480 msec and \<=500 msec at any postdose time point and not present at baseline QT or QTcF \>500 msec at any postdose time point and not present at baseline. QT/QTcF Increase from baseline \>60 msec for at least 1 postdose measurement. Increase from baseline in QT or QTcF \>30 msec for at least 1 postdose measurement, but \<=60 msec for all postdose measurements.
Time frame: Baseline to end of study (16 days)
20 August 2012 to 29 November 2012. Phase 1 Clinical Pharmacology center with healthy, fasted participants.
| Milestone | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 6 | 7 | 7 | 7 | 7 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
The geometric mean of the maximum observed plasma concentration (Cmax) is presented below; serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h,and 60 h postdose, relative to dosing on Day 1 in each cross over period and these data are summarized in the Pharmacokinetic (PK) parameter of Cmax presented here. Plasma samples were analyzed for dapagliflozin by High Performance Liquid chromatography-Mass Spectrometry (HPLC-MS/MS) using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Dapagliflozin Cmax was derived from plasma concentration versus time data using a non-compartmental method, using a validated PK analysis program ™. Actual sampling times were used for PK calculations. Cmax was reported in ng/mL.
| ng/mL | 10 mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population | 133 ± 23 | 125 ± 27 |
AUC(INF) is area under the plasma concentration-time curve from time 0 extrapolated to infinity. Serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Actual sampling times were used for PK calculations. AUC(INF) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
| ng*h/mL | 10 mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population | 547 ± 23 | 539 ± 20 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. Tmax was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours.
| hours | 10 mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population | 1.00 (0.50 to 2.02) | 1.00 (0.50 to 2.00) |
AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method). Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Actual sampling times were used for PK calculations. AUC(0-T) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
| ng*h/mL | 10 mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin | 529 ± 23 | 523 ± 19 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours.
| hours | 10mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Half-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population | 15.9 ± 7.32 | 13.8 ± 4.81 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). Cmax for Saxagliptin was derived from plasma concentration versus time data using a validated PK analysis program ™ and was measured in nanograms per milliliter (ng/mL).
| ng/mL | 5 mg Saxagliptin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Maximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population | 23.6 ± 31 | 21.9 ± 33 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. CLT/F was calculated as Dose/AUC(INF)and was measured in milliliters per minute (mL/min).
| mL/min | 10 mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Plasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population | 305 ± 24 | 309 ± 20 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). Actual sampling times were used for PK calculations. Cmax for 5-OH Saxagliptin (the major active metabolite of Saxagliptin) was derived from plasma concentration versus time data using a validated PK analysis program ™ and was measured in ng/mL.
| ng/mL | 10 mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Cmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population | 47.0 ± 30 | 49.6 ± 27 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(0-T), the area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
| ng*h/mL | 5 mg Saxagliptin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| AUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population | 87.8 ± 23 | 87.0 ± 23 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
| ng*h/mL | 5 mg Saxagliptin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population | 89.0 ± 23 | 88.2 ± 23 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method)and was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™. AUC (0-T) was measured in nanograms\*hours per milliliter (ng\*h/mL).
| ng*h/mL | 10 mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| AUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population | 267 ± 22 | 289 ± 22 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).
| ng*h/mL | 10 mg Dapagliflozin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| AUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population | 273 ± 22 | 296 ± 22 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Cmax of saxagliptin total active moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin) was derived from the plasma concentration versus time profile for the saxagliptin total active moiety. Measurement was in nano Molars (nM).
| nM | 5 mg Saxagliptin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Cmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population | 138 ± 20 | 137 ± 21 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. AUC(INF) is area under the plasma concentration-time curve from time zero extrapolated to infinity; AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) and both were derived from the plasma concentration versus time profile using a validated PK analysis program ™. Total moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin), AUC(0-T)and AUC(INF) were measured in nano Molars\*hours (nM\*h).
| nM*h | 5 mg Saxagliptin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| AUC(INF) for Saxagliptin Total Active Moiety | 702 ± 15 | 735 ± 15 |
| AUC(0-T) for Saxagliptin Total Active Moiety | 694 ± 15 | 727 ± 15 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin and 5-OH by LC-MS/MS using a validated method. Tmax was derived from the plasma concentration versus time profile for study drug and was measured in hours (h). Saxagliptin was the drug, 5-OH saxagliptin was the metabolite, and Saxagliptin total Active Moiety was molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin.
| h | 5 mg Saxagliptin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| Tmax of Saxagliptin | 0.50 (0.50 to 2.00) | 1.00 (0.50 to 2.00) |
| Tmax of 5-OH Saxagliptin | 1.50 (1.00 to 2.00) | 1.50 (1.00 to 3.00) |
| Tmax of Saxagliptin Total Active Moiety | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 2.00) |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours (h).
| h | 5 mg Saxagliptin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| T-HALF for Saxagliptin | 5.86 ± 2.23 | 5.38 ± 2.17 |
| T-HALF for 5-OH Saxagliptin | 15.9 ± 3.06 | 17.0 ± 2.97 |
Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Saxagliptin is the parent drug and 5-OH saxagliptin is the metabolite. The molecular weights to be used for the molar ratios were 315.42 and 331.42 for saxagliptin and 5-OH, respectively. Plasma samples were analyzed for saxagliptin and for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL and 0.200 ng/mL to 100.0 ng/mL for saxagliptin and 5-OH, respectively).
| Molar ratio | 5 mg Saxagliptin | 5 mg Saxagliptin + 10 mg Dapagliflozin |
|---|---|---|
| MR_Cmax | 1.90 ± 37 | 2.16 ± 37 |
| MR_AUC(INF) | 2.92 ± 33 | 3.19 ± 33 |
| MR_AUC(0-T) | 2.89 ± 33 | 3.16 ± 34 |
Adverse event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE)=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. End of study was approximately 16 days and was the time for a participant to conclude each of the 3 periods (including the 6 day washout between periods).
| participants | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| Participants with AEs | 6 | 9 | 8 |
| Participants with treatment-related AEs | 4 | 4 | 7 |
| Participants with SAEs | 0 | 0 | 0 |
| Participants discontinuing due to AEs | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 |
Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal (LLN); upper limit of normal (ULN); pretreatment(pre-RX); treatment (RX). Hemoglobin (g/L): \<0.85\* pre-RX; hematocrit (vol): \<0.85\*pre-RX; erythrocytes (\*10\^12 c/L): \<0.85\*pre-RX; platelet count (\*10\^9 c/L): \<0.85\*LLN if pre-RX\>=LLN, or if Pre-Tx \<LLN; leukocytes (\*10\^9 c/L): \<0.85\*LLN if pre-RX \<LLN,or \<0.9\*LLN if LLN\<=Pre-RX\<=ULN; neutrophils+bands (\*10\^9 c/L): \<0.85\*Pre-RX if Pre-RX \<1.5 or \<1.5 if Pre-RX \>=1.5; eosinophils (\*10\^9 c/L): if value \>0.75; basophils (\*10\^9 c/L): if value \>0.4; monocytes (\*10\^9c/L): if value \>2; lymphocytes (\*10\^9 c/L): if value \<0.750 or if value \>7.50.
| participants | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| Leukocytes Low | 0 | 0 | 1 |
| Neutrophils (absolute) Low | 1 | 1 | 1 |
Blood pressure was taken while the participant was quietly seated for at least 5 minutes. Blood pressure was measured in millimeters of mercury (mmHg). Baseline was Day -1 in Period 1; study drug was administered on Day 1 of each crossover period.
| mmHg | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| Systolic Blood Pressure | -6.0 ± 7.41 | -4.6 ± 8.13 | -7.2 ± 8.35 |
| Diastolic Blood Pressure | -2.6 ± 4.94 | -2.0 ± 4.86 | -3.3 ± 6.23 |
Heart rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in beats per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.
| bpm | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| Mean Change From Baseline in Heart Rate - Safety Population | -4.4 ± 7.04 | -4.0 ± 9.64 | -4.3 ± 10.52 |
Respiration rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in breaths per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.
| bpm | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| Mean Change From Baseline in Respiration Rate - Safety Population | -0.4 ± 3.46 | -1.2 ± 2.89 | -0.9 ± 3.13 |
Participant had their temperature taken after quietly sitting for at least 5 minutes and it was measured as degrees of centigrade (C). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.
| degrees of centigrade | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| Mean Change From Baseline in Temperature - Safety Population | -0.15 ± 0.393 | -0.23 ± 0.383 | -0.16 ± 0.385 |
Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal(LLN); upper limit of normal (ULN); pre-treatment(Pre-Rx). Alkaline phosphatase U/L:\>1.25\*Pre-RX if Pre-Rx \>ULN or \>1.25\*ULN if Pre-Rx \<=ULN; aspartate aminotransferase (AST) U/L: \>1.25\*Pre-Rx if Pre-Rx \> ULN or 1.25\*ULN if Pre-Rx \<= ULN;alanine aminotransferase (ALT) U/L: \>1.25\*Pre-Rx if Pre-Rx\>ULN or 1.25\*ULN if Pre-Rx\<=ULN;blood urea nitrogen (BUN)mmol/L: \>1.1\*ULN if Pre-Rx \<=ULN or \>1.2\*Pre-Rx if Pre-Rx \>ULN; total bilirubin µmol/L: \>1.1\*ULN if Pre-Rx \<=ULN or \>1.25\*Pre-Rx if Pre-Rx \>ULN;direct bilirubin µmol/L: \>1.1\*ULN if Pre-Rx \<= ULN or \>1.25\*Pre-Rx if Pre-Rx \> ULN; creatine phosphokinase (CK) U/L: \>1.5\*Pre-Rx if Pre-Rx \>ULN or \>1.5\*ULN if Pre-Rx \<= ULN.
| participants | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| Total Bilirubin High | 1 | 1 | 1 |
| Direct Bilirubin High | 1 | 1 | 1 |
| ALT High | 1 | 0 | 1 |
| BUN High | 1 | 0 | 0 |
| CK High | 0 | 0 | 1 |
Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Fasted for 10 hours prior to samples taken. LLN=lower limit of normal; ULN=upper limit of normal; pretreatment (Pre-Rx). Normals: Urine glucose qualitative: dipstick \>=1 if Pre-Rx \<1 or 2\*Pre-Rx if Pre-Rx\>=1; urine microscopic white blood cell count (WBC): \>=2 if Pre-Rx \<2 or \>=4 if Pre-Rx \>=2;urine red blood cell count (RBC):\>=2 if Pre-Rx \<2 or \>=4 if Pre-Rx \>=2.
| participants | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| Urine Glucose High (N=42, 42, 42) | 0 | 2 | 5 |
| Urine WBC and RBC High (N= 4, 8, 6) | 0 | 0 | 1 |
A 12-Lead electrocardiogram (ECG) was performed and recorded after the participant had been supine for at least 5 minutes. ECGs done at baseline (Day-1 of Period 1) and at end of study; therefore the results are presented by sequence, and cannot be presented by treatment. QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec). Abnormality criteria: QT/QTcF QT or QTcF \>450 msec and \<=480 msec at any postdose time point and not present at baseline. QT or QTcF \>480 msec and \<=500 msec at any postdose time point and not present at baseline QT or QTcF \>500 msec at any postdose time point and not present at baseline. QT/QTcF Increase from baseline \>60 msec for at least 1 postdose measurement. Increase from baseline in QT or QTcF \>30 msec for at least 1 postdose measurement, but \<=60 msec for all postdose measurements.
| participants | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin |
|---|---|---|---|---|---|---|
| QT change from baseline >60 msec | 0 | 0 | 0 | 1 | 0 | 0 |
| QT change from baseline >30 msec; <=60 msec | 0 | 4 | 0 | 0 | 0 | 0 |
| QTcF change from baseline >60 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF change from baseline >30 msec; <=60 msec | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Day -1 to end of study (approximately 16 days). Total length of 3 crossover periods.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Saxagliptin 5mg | — | 0/42 (0%) | 6/42 (14.3%) |
| Treatment B: Dapagliflozin 10mg | — | 0/42 (0%) | 9/42 (21.4%) |
| Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg | — | 0/42 (0%) | 8/42 (19%) |
| Event | Treatment A: Saxagliptin 5mg | Treatment B: Dapagliflozin 10mg | Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 0/42 | 2/42 | 4/42 |
| ConstipationGastrointestinal disorders | 2/42 | 1/42 | 2/42 |
| DysmenorrheaReproductive system and breast disorders | 0/42 | 2/42 | 1/42 |
| NauseaGastrointestinal disorders | 0/42 | 2/42 | 0/42 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/42 | 1/42 | 0/42 |
| Abdominal distensionGastrointestinal disorders | 1/42 | 0/42 | 0/42 |
| Abdominal painGastrointestinal disorders | 0/42 | 0/42 | 1/42 |
| Abdominal Pain LowerGastrointestinal disorders | 1/42 | 0/42 | 0/42 |
| ALT increasedInvestigations | 0/42 | 0/42 | 1/42 |
| Back painMusculoskeletal and connective tissue disorders | 1/42 | 0/42 | 0/42 |
| Age, Categorical(Participants) | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 7 | 7 | 7 | 7 | 7 | 42 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin | Total |
|---|---|---|---|---|---|---|---|
| Mean | 36.1 ± 6.47 | 28.7 ± 5.02 | 27.7 ± 6.99 | 32.0 ± 6.51 | 34.4 ± 5.74 | 33.3 ± 7.95 | 32.0 ± 6.81 |
| Sex: Female, Male(Participants) | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 2 | 3 | 2 | 2 | 13 |
| Male | 5 | 5 | 5 | 4 | 5 | 5 | 29 |
| Region of Enrollment(participants) | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin | Total |
|---|---|---|---|---|---|---|---|
| United States | 7 | 7 | 7 | 7 | 7 | 7 | 42 |
| Body Surface Area (m^2)(m^2) | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin | Total |
|---|---|---|---|---|---|---|---|
| Mean | 1.90 ± 0.187 | 1.92 ± 0.145 | 1.91 ± 0.208 | 1.95 ± 0.170 | 1.94 ± 0.166 | 1.85 ± 0.108 | 1.91 ± 0.160 |
| Body Weight (kg)(kg) | A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) | A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin | B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) | B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin | C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin | C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin | Total |
|---|---|---|---|---|---|---|---|
| Mean | 77.94 ± 12.250 | 78.94 ± 8.100 | 76.01 ± 14.589 | 80.73 ± 11.903 | 79.64 ± 11.223 | 71.71 ± 6.404 | 77.50 ± 10.813 |
The record gives a start of Aug 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Dapagliflozin